Testing Zelquistinel for major depression
Part of Mental health clinical trials.
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You currently have a major depressive episode that started between 3 weeks and 18 months ago.
- You have not tried 2 or more antidepressants that failed to help in this current episode.
- You do not have certain other mental health conditions like bipolar disorder, OCD, PTSD, or panic attacks.
- You have not used ketamine, esketamine, or any psychedelic drug for depression in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called BMS-986511 for adults with major depressive disorder. It aims to see if the drug can help relieve depression symptoms more effectively than a placebo.
This study tests whether zelquistinel, an investigational drug, can reduce symptoms of major depressive disorder (a type of clinical depression). It is for people who are currently experiencing a moderate to severe depressive episode and are not taking other antidepressants.
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
This trial tests if adding a statin (a cholesterol-lowering medicine) to your current depression treatment improves symptoms. It is for adults aged 20 to 45 with mild to moderate depression who are not already taking a statin.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.